176 related articles for article (PubMed ID: 29630134)
21. Plasma Inflammatory Cytokine IL-4, IL-8, IL-10, and TNF-α Levels Correlate with Pulmonary Function in Patients with Asthma-Chronic Obstructive Pulmonary Disease (COPD) Overlap Syndrome.
Huang AX; Lu LW; Liu WJ; Huang M
Med Sci Monit; 2016 Aug; 22():2800-8. PubMed ID: 27501772
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary aspergillosis presenting with recurrent haemoptysis.
Betancourt BY; Garofoli AC; Sandhu JS; Boma N; Sy AM
BMJ Case Rep; 2015 Jul; 2015():. PubMed ID: 26153296
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary Mycobacterium parascrofulaceum Infection in a Patient with Chronic Progressive Pulmonary Aspergillosis: A Case Report and Literature Review.
Ikegami H; Yamasaki K; Kawanami T; Fukuda K; Akata K; Nakamura M; Ikushima I; Fukuda Y; Noguchi S; Yatera K
Intern Med; 2020 Jun; 59(11):1417-1422. PubMed ID: 31866624
[TBL] [Abstract][Full Text] [Related]
24. Voriconazole-induced periostitis in a patient with overlap syndromes.
Hirota K; Yasoda A; Fujii T; Inagaki N
BMJ Case Rep; 2014 Mar; 2014():. PubMed ID: 24599432
[TBL] [Abstract][Full Text] [Related]
25. [Short-term efficacy evaluation of chronic pulmonary aspergillosis treated with micafangin and maintenance therapy of itraconazole].
Yasuda S; Ohnishi R; Suzuki T; Sano K; Kato T
Nihon Kokyuki Gakkai Zasshi; 2009 Nov; 47(11):985-90. PubMed ID: 19994592
[TBL] [Abstract][Full Text] [Related]
26. Chronic Pulmonary Aspergillosis with Pleuroparenchymal Fibroelastosis-like Features.
Kushima H; Ishii H; Kinoshita Y; Fujita M; Watanabe K
Intern Med; 2019 Apr; 58(8):1137-1140. PubMed ID: 30568135
[TBL] [Abstract][Full Text] [Related]
27. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model.
Takemoto K; Yamamoto Y; Ueda Y; Kanazawa K; Yoshida K; Niki Y
Chemotherapy; 2009; 55(2):105-13. PubMed ID: 19151551
[TBL] [Abstract][Full Text] [Related]
28. Tolerability of oral itraconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A systematic review and meta-analysis.
Olum R; Baluku JB; Kazibwe A; Russell L; Bongomin F
PLoS One; 2020; 15(10):e0240374. PubMed ID: 33052954
[TBL] [Abstract][Full Text] [Related]
29. [A case of pulmonary alternariosis complicated with aspergillosis].
Tan Y; Song M; Peng H; Guo W; Zhou Q; Long Y; Luo M; Chen P
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Sep; 42(9):1122-1128. PubMed ID: 28989162
[TBL] [Abstract][Full Text] [Related]
30. [Clinical case of the month. Pulmonary aspergillosis: chimic necrotizing aspergillosis].
Golinval O; Louis R
Rev Med Liege; 2007 Dec; 62(12):704-6. PubMed ID: 18286944
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies.
Raad II; Zakhem AE; Helou GE; Jiang Y; Kontoyiannis DP; Hachem R
Int J Antimicrob Agents; 2015 Mar; 45(3):283-8. PubMed ID: 25455847
[TBL] [Abstract][Full Text] [Related]
32. Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations.
Muilwijk EW; Dekkers BGJ; Henriet SSV; Verweij PE; Witjes B; Lashof AMLO; Groeneveld GH; van der Hoeven J; Alffenaar JWC; Russel FGM; van de Veerdonk F; Brüggemann RJM
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28717040
[TBL] [Abstract][Full Text] [Related]
33. Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature.
Pena TA; Soubani AO; Samavati L
Lung; 2011 Apr; 189(2):167-72. PubMed ID: 21327836
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H
Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679
[TBL] [Abstract][Full Text] [Related]
35. Management of voriconazole hepatotoxicity in a lung transplant patient.
Belaiche S; Roustit M; Bedouch P; Quetant S; Saint-Raymond C; Pison C
Transpl Infect Dis; 2011 Jun; 13(3):309-11. PubMed ID: 21176020
[TBL] [Abstract][Full Text] [Related]
36. Toward the personalized and integrative management of voriconazole dosing during COVID-19-associated pulmonary aspergillosis.
Le Daré B; Boglione-Kerrien C; Reizine F; Gangneux JP; Bacle A
Crit Care; 2021 Apr; 25(1):152. PubMed ID: 33879175
[No Abstract] [Full Text] [Related]
37. Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India.
Sehgal IS; Dhooria S; Muthu V; Prasad KT; Aggarwal AN; Chakrabarti A; Choudhary H; Garg M; Agarwal R
Lancet Infect Dis; 2022 Jul; 22(7):1052-1061. PubMed ID: 35429465
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of a respiratory rehabilitation exercise training package in hospitalized elderly patients with acute exacerbation of COPD: a randomized control trial.
Liao LY; Chen KM; Chung WS; Chien JY
Int J Chron Obstruct Pulmon Dis; 2015; 10():1703-9. PubMed ID: 26345529
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of refractory chronic necrotizing pulmonary aspergillosis with micafungin.
Ouchi H; Fujita M; Ikegame S; Inoshima I; Harada E; Nakanishi Y
J Infect Chemother; 2007 Aug; 13(4):258-62. PubMed ID: 17721689
[TBL] [Abstract][Full Text] [Related]
40. Pneumonia with an unusual outcome in an immunocompetent patient.
Sánchez-Jareño M; Martínez Verdasco A; Esteban Rodriguez I; Álvarez-Sala R
Enferm Infecc Microbiol Clin (Engl Ed); 2018; 36(6):382-383. PubMed ID: 28238503
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
